Treats advanced prostate cancer. Sold as Firmagon. Every FDA application for this active ingredient: 1 branded and 1 generic.
As of Nov 15, 2026, FDA lists 2 applications for Degarelix Acetate (sold as Firmagon), first approved Dec 24, 2008, with 0 new uses approved and 0 published complete response letters.
| Firmagon | Part B | $14.5M | -15% | 8,701 |
| Firmagon | Part D | $1.2M | +1% | 445 |
| Assessing Efficacy of Neoadjuvant ADT in Localized High-Risk Prostate Cancer Patients Utilizing 18F-Flotufolastat PSMA PET/CTProstate Cancer, Localized Prostate Carcinoma · Baptist Health South Florida | Phase 2 | Recruiting | Mar 6, 2026 |
| Safety and Efficacy Evaluation of LC-K76 in Patients With Metastatic Hormone-Sensitive Prostate CancermHSPC, mHNPC · Shanghai Changzheng Hospital | Early phase 1 | Not yet recruiting | Feb 5, 2026 |
| Supraphysiologic Testosterone Priming Induces Darolutamide Extended ResponseMetastatic Castration-resistant Prostate Cancer · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Phase 2 | Recruiting | Aug 26, 2025 |
| The COSMYC Trial (COmbined Suppression of MYC)Metastatic Castration-resistant Prostate Cancer · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Phase 2 | Recruiting | Apr 10, 2025 |
| Stereotactic Body Radiation Therapy Plus Immediate or Delayed Androgen Receptor Pathway Inhibitor and Androgen Deprivation Therapy or Salvage Radiation Therapy for the Treatment of Prostate Cancer, DIVINE TrialRecurrent Castration-Sensitive Prostate Carcinoma, Recurrent Prostate Cancer · Mayo Clinic | Phase 2 | Recruiting | Apr 23, 2024 |
| Treatment of High-Risk Prostate Cancer Guided by Novel Diagnostic Radio- and Molecular TracersProstate Cancer · Cancer Research Antwerp | Phase 2 / Phase 3 | Recruiting | Feb 28, 2024 |
| Cardiometabolic Consequences of the Loss of Ovarian FunctionMenopause, Estrogen Deficiency · University of Colorado, Denver | Phase 4 | Recruiting | Feb 20, 2024 |
| Difluoromethylornithine and High Dose Testosterone With Enzalutamide in Metastatic Castration-Resistant Prostate CancerProstate Cancer · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Phase 2 | Recruiting | Sep 28, 2023 |
| Dec 24, 2008 | FirmagonNDA 22201 · New molecular entity | Ferring | 12 | Marketed |
| — | Degarelix AcetateANDA 215791 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 0 | Discontinued |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA